# EDGAR Filing Document

**Accession Number:** 0001093557
**File Stem:** 0001093557-25-000264
**Filing Date:** 2025-10
**Character Count:** 12418
**Document Hash:** 600b82e6716d0216d052076b15fa06a4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001093557-25-000264.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0001093557-25-000264

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251024

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251027

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DEXCOM INC
- **CENTRAL INDEX KEY:** 0001093557
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330857544
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51222
- **FILM NUMBER:** 251420065

**BUSINESS ADDRESS:**
- **STREET 1:** 6340 SEQUENCE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 8582000200

**MAIL ADDRESS:**
- **STREET 1:** 6340 SEQUENCE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

?xml version='1.0' encoding='ASCII'? dxcm-20251024

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): October 24, 2025**

![dexcom-logo-green-rgb.jpg](dxcm-20251024_g1.jpg)

**DEXCOM, INC.**

**(Exact Name of the Registrant as Specified in Its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-51222** | **33-0857544** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **6340 Sequence Drive, San Diego, CA** | **92121** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**(858) 200-0200**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, $0.001 Par Value Per Share | DXCM | Nasdaq Global Select Market |

---

---

| | | |
|:---|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |
| | Emerging growth company  | ☐  |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

------

**ITEM 5.02.&nbsp;&nbsp;&nbsp;&nbsp;DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.**

On October 24, 2025, the Board of Directors (the "Board") of DexCom, Inc. ("Dexcom" or the "Company"), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to ten directors and appointed Dr. Euan Ashley as a director, effective immediately. Dr. Ashley will hold office for a term expiring at the 2026 annual meeting of Dexcom's stockholders (the "2026 Annual Meeting"). The Board also appointed Dr. Ashley to serve as a member of the Nominating and Governance Committee (the "Nominating Committee") and the Technology Committee of the Board, effective immediately. In connection with Dr. Ashley's appointment to the Nominating Committee, Kyle Malady will step down as a member of the Nominating Committee but continue in his role as chair of the Technology Committee.

As previously disclosed, on July 30, 2025, the Company filed a Current Report on Form 8-K to announce, among other things, the increase in the size of the Board to ten directors effective January 1, 2026, and the appointment of Jacob S. Leach as a director effective January 1, 2026, provided he continues to provide services to the Company. In connection with Dr. Ashley's appointment, on October 24, 2025, the Board also increased the size of the Board from ten to eleven directors effective January 1, 2026, and confirmed the previous appointment of Mr. Leach as a director effective January 1, 2026, provided he continues service with the Company.

There is no arrangement or understanding between Dr. Ashley and any other persons pursuant to which Dr. Ashley was selected as a director. Dr. Ashley is not a party to and does not have any direct or indirect material interest in any transaction with Dexcom required to be disclosed under Item 404(a) of Regulation S-K. The Board determined that Dr. Ashley qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of the Nasdaq Stock Market, in each case as currently in effect. Dr. Ashley also entered into Dexcom's standard form of indemnity agreement for its directors and executive officers, which was filed as Exhibit 10.43 to Dexcom's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on February 11, 2021.

In accordance with Dexcom's non-employee director compensation program, upon his appointment Dr. Ashley was granted an initial appointment equity grant of restricted stock units ("RSUs") with a fair value of $500,000, vesting annually over the three years following the date of grant, subject to Dr. Ashley's continued service. Dr. Ashley will also be eligible to receive the annual equity grant to non-employee directors on or around the 2026 Annual Meeting in the form of a grant of RSUs with a fair value of $345,000 for his service on the Board and committees. The annual award vests on the earlier of the date of the first annual stockholder meeting thereafter or one year from the date of grant, subject to continued service. Vesting of outstanding equity awards held by non-employee directors is accelerated in full upon a change in control of Dexcom.

**ITEM 7.01.&nbsp;&nbsp;&nbsp;&nbsp;REGULATION FD DISCLOSURE.**

On October 27, 2025, Dexcom announced the appointment of Dr. Ashley to the Board in a press release furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

**ITEM 9.01.&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND EXHIBITS.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Number** | **Description** |
| 99.1 | <u>[Press release dated October 27, 2025](dxcm20251024-exhibit991.htm)</u> |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **DEXCOM, INC.** | **DEXCOM, INC.** |
| By: | <u>/s/ JEREME M. SYLVAIN</u><br>Jereme M. Sylvain<br>Executive Vice President, Chief Financial Officer |
| Date: | October 27, 2025 |

---

## Exhibit 99.1

**Exhibit 99.1**

**Dexcom Appoints Euan Ashley to Board of Directors**

SAN DIEGO - (BUSINESS WIRE- October 27, 2025) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.

Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-director of Stanford's biomedical innovation-translation program, Catalyst, which invests in the university's most promising biomedical innovations. Dr. Ashley brings to the Dexcom Board a leading clinical perspective for strategic guidance related to medical technology development and healthcare innovation.

"As I recently completed my Dexcom Board service and collaborated with management on clinical leaders who share my and Dexcom's vision to empower greater metabolic health, Euan was at the top of my list," said Eric Topol, M.D., Director of the Scripps Translational Science Institute. "He will provide an excellent perspective for Dexcom as they build on their incredible growth journey."

"We are thrilled to announce Euan's appointment to the Dexcom Board today," said Jake Leach, president and interim CEO at Dexcom. "Dexcom is well-positioned to advance metabolic health and improve quality of life for millions of people globally. Euan's leadership across the intersections of clinical practice and key advances in healthcare innovation will strengthen us as we continue to advance our biosensing technology across the spectrum of metabolic health."

**About Euan Ashley**

Dr. Euan Ashley currently serves as Chair of the Department of Medicine of Stanford University. Dr. Ashley has held various roles at Stanford University since 2006, including Chair of the Department of Medicine from 2024 to present, Associate Dean from 2019 to 2024, Co-Director of Stanford Medicine Catalyst from 2019 to present, and Professor of Medicine, Genetics and Biomedical Data Science from 2006 to present. Dr. Ashley founded the Center for Inherited Cardiovascular Disease in 2009 and the Clinical Genomics program in 2014. Dr. Ashley has founded several biotechnology companies including Personalis Inc. ($PSNL) a personalized cancer testing company (2012); Deepcell, Inc., a single cell analysis company (2016); Svexa, a human performance artificial intelligence company (2019); Saturnus Bio, a therapeutics company (2024); and Swift Bio, a genomic diagnostics company (2025). From 2020 to present, Dr. Ashley has served on the Board of Directors of AstraZeneca Plc, a pharmaceutical company.

Dr. Ashley received a Bachelor's degree in Physiology from the University of Glasgow, a Doctor of Medicine from the University of Glasgow, and a Doctor of Philosophy from the University of Oxford. He was trained in Cardiology at Stanford University.

**About DexCom, Inc.**

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

Category: IR

**<u>Media Contact</u>**

James McIntosh

619-884-2118

mediarelations@dexcom.com

**<u>Investor Contact</u>**

Sean Christensen

858-203-6657

investor-relations@dexcom.com

<br>